{
  "x402Version": 2,
  "id": 4544,
  "slug": "4544",
  "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis",
  "description": "Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.",
  "type": "http",
  "accepts": [
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "200000",
      "maxTimeoutSeconds": 604900
    },
    {
      "scheme": "exact",
      "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
      "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
      "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:137",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:42161",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:480",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:143",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:196",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:999",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
      "payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
      "asset": "31566704",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "XRP",
      "amount": "200000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "524C555344000000000000000000000000000000",
      "amount": "0.2",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:56",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
      "amount": "200000000000000000",
      "maxTimeoutSeconds": 300
    }
  ],
  "outputSchema": {
    "bazaar": {
      "info": {
        "input": {
          "method": "GET",
          "queryParams": {
            "condition": "Disease — e.g. \"Alzheimer Disease\" | \"Sepsis\" | \"ALS\" | \"Depression\" | \"NASH\"",
            "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)"
          },
          "type": "http"
        },
        "output": {
          "example": {
            "failure_taxonomy": {
              "operational_failures": {
                "examples": [
                  "COVID-19 disruption, enrollment failures in rare AD subpopulations"
                ],
                "pct": 4
              },
              "safety_termination": {
                "examples": [
                  "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"
                ],
                "key_trials": [
                  "Aducanumab Phase 3 dose arm"
                ],
                "pct": 8
              },
              "wrong_endpoint": {
                "examples": [
                  "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"
                ],
                "key_trials": [
                  "Multiple agents 2010-2020"
                ],
                "pct": 18
              },
              "wrong_patient_population": {
                "examples": [
                  "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"
                ],
                "key_trials": [
                  "Bapineuzumab (mild-moderate vs. early)"
                ],
                "pct": 28
              },
              "wrong_target_or_hypothesis": {
                "examples": [
                  "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"
                ],
                "key_trials": [
                  "Solanezumab",
                  "Verubecestat",
                  "Atabecestat"
                ],
                "pct": 42
              }
            },
            "historical_success_rates": {
              "overall_clinical_success_pct": 3.4,
              "phase2_to_phase3_pct": 31,
              "phase3_to_approval_pct": 11,
              "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)"
            },
            "lessons_learned": [
              "Early intervention is critical — treat pre-symptomatic or MCI only",
              "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)",
              "CDR-SB global score now accepted primary endpoint by FDA (post-2018)",
              "ARIA management protocols must be pre-specified — not post-hoc",
              "Combination approaches (amyloid + tau + neuroinflammation) likely needed"
            ],
            "query_summary": {
              "condition": "Alzheimer Disease",
              "trials_analyzed": 78
            },
            "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration.",
            "what_still_might_fail": [
              "Tau-targeting agents if amyloid clearance alone sufficient",
              "Agents tested in wrong disease stage despite lessons",
              "CNS inflammation approaches without biomarker stratification"
            ]
          },
          "type": "json"
        }
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "properties": {
          "input": {
            "additionalProperties": false,
            "properties": {
              "method": {
                "enum": [
                  "GET",
                  "HEAD",
                  "DELETE"
                ],
                "type": "string"
              },
              "queryParams": {
                "properties": {
                  "condition": {
                    "type": "string"
                  },
                  "lang": {
                    "type": "string"
                  }
                },
                "type": "object"
              },
              "type": {
                "const": "http",
                "type": "string"
              }
            },
            "required": [
              "type",
              "method"
            ],
            "type": "object"
          },
          "output": {
            "properties": {
              "example": {
                "type": "object"
              },
              "type": {
                "type": "string"
              }
            },
            "required": [
              "type"
            ],
            "type": "object"
          }
        },
        "required": [
          "input"
        ],
        "type": "object"
      }
    },
    "builder-code": {
      "info": {
        "a": "bc_gxy6qn5p"
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "additionalProperties": false,
        "properties": {
          "a": {
            "description": "App builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          },
          "s": {
            "description": "Service builder codes",
            "items": {
              "pattern": "^[a-z0-9_]{1,32}$",
              "type": "string"
            },
            "type": "array"
          },
          "w": {
            "description": "Wallet builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          }
        },
        "type": "object"
      }
    }
  },
  "tags": [
    "bazaar",
    "builder-code"
  ],
  "sourceHost": "clinicalintelpulse.theaslangroupllc.com",
  "lastUpdated": "2026-08-20T14:01:58.035Z",
  "quality": {
    "calls30d": 1,
    "uniquePayers30d": 1,
    "lastCalledAt": "2026-08-20T14:01:57.888Z"
  },
  "liveness": {},
  "verified": false,
  "featured": false,
  "provider": {
    "host": "clinicalintelpulse.theaslangroupllc.com",
    "manifest_name": "clinicalintelpulse.theaslangroupllc.com",
    "source": "cdp-mirror",
    "source_manifest_url": "https://api.cdp.coinbase.com/platform/v2/x402/discovery/resources",
    "submitted_at": "2026-09-18T22:00:31.484Z"
  }
}